Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Eli Lilly’s Trulicity App Seeks to Improve Medication Adherence

XTALKS VITALS NEWS

App

Pharmaceutical giant, Eli Lilly, launched a free-to-download app in March for their type 2 diabetes drug, Trulicity.

Share this!

December 1, 2016 | by Sarah Hand, M.Sc.

Pharmaceutical companies are increasing looking to branded apps to inform patients about medicines, and potential help increase medication adherence. Pharmaceutical giant, Eli Lilly, launched a free-to-download app in March for their type 2 diabetes drug, Trulicity.

Approved in 2014, Trulicity saw a 70 percent increase in sales in the third quarter of 2016 – bringing in $243.6 million in revenue – compared to the same quarter in 2015. Now, Eli Lilly is looking to continue this upward trend by marketing their Trulicity app alongside sample packs of the drug, during sales visits with physicians.

Since Trulicity is a weekly diabetes treatment, patients used to taking a daily medication for disease management could forget to take their dose. While the app was initially built to address this issue of medication adherence, Eli Lilly decided that the experience of using the app would need to be further improved for its users.

“That's when we started building in a bunch of additional functionalities to try to connect our patients to some of our other resources,” Juan Granados-Zuniga, Eli Lilly's associate brand manager of consumer marketing in diabetes, told Medical Marketing & Media. Everything from FAQs to answering real-time questions they might have, to getting them a savings card, to watching videos on what to expect when getting them started.”



As Trulicity is administered via an injection pen, Eli Lilly is especially focused on helping patients use the medical device correctly. Their branded app includes a demo of how the pen functions, along with the sound it makes when it is used. According to Eli Lilly, this is one of their app’s most used feature.

“It's used in some cases as a training tool and is essentially augmented reality,” said Granados-Zuniga. “It gives you the sense of how to use the pen if you don't have the pen on you or if you're trying to learn how to use it, it's interactive.”

Eli Lilly currently has two branded apps available for user download, the second of which is for their other diabetes drug, Glucagon. According to Granados-Zuniga, the Trulicity app has been downloaded 2,500 times with around 46,000 total logged sessions.

Despite their success, Granados-Zuniga says that branded apps aren’t appropriate for all pharmaceutical products and medical devices. He goes on to say that working with a partner company with an established app can be the best way to engage consumers.

“Ideally, it would be wonderful for branded apps to live within the umbrella of a CVS or Walgreens app because my goal is not to have somebody overwhelmed by 75 different health-related apps on their phone,” said Granados-Zuniga. “We try to talk about innovative ways to integrate them into different workflows for people because we do think that it's the right thing to do, to create a better experience ultimately.”


Keywords: Pharmaceutical Company, Medication Adherence, Health App


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Gilead’s Newest Hepatitis C Drug Gets FDA Approval

July 21, 2017 - Dominant player in the chronic hepatitis C virus (HCV) market Gilead has received US Food and Drug Administration (FDA) approval for its newest treatment, Vosevi.

Featured In: Pharmaceutical News


Detecting Alzheimer’s Biomarkers in the Blood Could Improve Early Diagnosis

July 20, 2017 - In an effort to improve rates of early diagnosis and intervention, researchers at Washington University in St. Louis have developed a blood test that can detect some of the hallmarks of Alzheimer’s disease.

Featured In: Biotech News


Insurance Coverage Under the Affordable Care Act Supports Clinical Trial Enrollment, Says Study

July 20, 2017 - Since the Patient Protection and Affordable Care Act (ACA) was passed in 2010, insurance approval for patients wishing to participate in oncology clinical trials has increased, according to a recent study published in the journal, Clinical Cancer Research.

Featured In: Clinical Trial News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Manufacturing Control Strategies: What Pharmaceutical and Biotech Companies Need to Know

REGISTER FOR THESE WEBINARS

Outsourcing Pharmacovigilance: Pros and Cons and Lessons Learned


EDC and eSource: Combined for Better Data and Faster Insights


Using Model Reduction to Bridge the Quality Systems Pharmacology-Pharmacometrics Divide


How to Maximize Your Non-GLP Toxicology Studies: A Guide for Optimal Design and Methodology


Copyright © 2016-2017 Honeycomb Worldwide Inc.